サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1304512

ブレストイメージングの世界市場-2023年～2030年

Global Breast Imaging Market - 2023-2030
出版日: | 発行: DataM Intelligence | ページ情報: 英文 195 Pages | 納期: 約2営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=157.14円
ブレストイメージングの世界市場-2023年～2030年
出版日: 2023年07月07日
発行: DataM Intelligence
ページ情報: 英文 195 Pages
納期: 約2営業日
ご注意事項 :
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 目次
概要

市場概要

世界のブレストイメージング市場は2022年に42億米ドルに達し、2030年には79億米ドルに達することで有利な成長を示すと予測されています。世界のブレストイメージング市場は、予測期間2023-2030年にCAGR 8.4%を示すと予測されています。技術進歩の増加や新製品への投資の増加が、ブレストイメージング市場の動向に対する需要を押し上げています。

ブレストイメージング市場には、製品の存在を確立するモダリティとアプリケーションが含まれます。女性に多いにもかかわらず、乳がんは男性も罹患する可能性があります。超音波検査、核磁気共鳴画像法（MRI）、マンモグラフィ、サーモグラフィは、乳がんや関連疾患の検出に最も頻繁に使用されるブレストイメージング診断法です。新しいモダリティの発売とがん患者の増加が、ブレストイメージング診断の世界市場を推進している主な要因です。

ブレストイメージング診断の市場範囲は、乳がん、乳腺疾患、その他などのアプリケーションで構成されており、ブレストイメージング診断の市場シェアを拡大しています。ブレストイメージング診断の世界市場は、研究開発の増加や各国での今後の新製品承認などの要因の結果として拡大しており、ブレストイメージング診断市場の成長にも明るい見通しを生み出しています。

市場力学

技術の進歩がブレストイメージング市場の成長を促進する

マンモグラフィは、放射線科医の乳がん画像診断ツールセットの重要な構成要素として存在してきました。その誕生以来、この疾患の死亡率を劇的に低下させ、乳がんを迅速に特定するための重要なスクリーニングおよび診断ツールとなっています。

マンモグラフィは、フィルムからデジタルマンモグラフィを経てデジタルブレストトモシンセシス（DBT）へと、技術とともに進歩してきました。がんの発見率を高め、偽陽性を減らし、治療成績を向上させるために、進化のたびに放射線科医が直面する問題や患者の悩みに取り組み続けてきました。

ブレストイメージング診断の次なる発展となりうる造影マンモグラフィ（CEM）は、この進化の結果です。この技術が誕生したのは10年近く前のことだが、従来の補助的な画像診断に対する優位性を強調する調査結果が次々と発表され、最近になってようやく注目され始めました。

乳房組織の異常を検出するために、CEMはCT（コンピュータ断層撮影）技術と同じ造影剤を使用します。造影剤は血管を経由して乳房組織内を流れ、病変が形成されたり増大したりする場所に集積し、CTや磁気共鳴画像法（MRI）と同様の物理的イメージング概念を用います。

研究開発と新製品上市の増加がメーカーに有利な機会を生み出す

乳がん発症リスクが平均的な50～74歳の女性は、USPSTFにより2年に1回マンモグラフィを受けるよう勧告されています。40歳から49歳の女性は、いつから、どれくらいの頻度でマンモグラフィを受けるべきか、医師または他の医師と相談する必要があります。

例えば、2022年5月、AIベースのソフトウェアを作成する女性の健康のための組織であるTherapixelは、MammoScreen 2Dおよび3Dを発表しました。以前の検査結果と比較することで、MammoScreenはより効果的になります。

装置に関する制限が市場の成長を妨げる

2年に1度の20年間の乳がん検診スケジュールで、すべての種類の乳がんが発見されるわけではないです。2年に1回のマンモグラフィ検診を20年間受けた女性1,000人中77人が乳がんを発症します。そのうち21人は、マンモグラフィの結果が正常であるにもかかわらず、がんの診断を受けることになります。

このようなことが起こる可能性があるのは、乳がんにかかった人が全員生存している場合、マンモグラフィでがんが発見されなかった場合、マンモグラフィを受けた時点でがんが確定していなかった場合などです。マンモグラフィを2年ごとに20年間受けた女性1,000人中13人が乳がんで亡くなると予測されています。マンモグラフィもX線検査です。X線検査では、他の検査と同様に放射線が放出されます。

COVID-19影響分析

COVID-19の流行と世界の封鎖は、あらゆる業界の企業の財務状況に影響を及ぼしています。その結果、米国食品医薬品局（FDA）は、COVID-19健康緊急事態の期間中、スポンサーと研究者を支援し、試験参加者の安全を確保し、適正臨床実施（GCP）に従い、試験の完全性に対するリスクを低減するための一般的な考慮事項を含むガイドラインを発表しました。

ロシア・ウクライナ紛争の影響分析

ロシアとウクライナの紛争は、この地域の主要な市場プレーヤーの数が少ないため、世界のブレストイメージング診断市場への影響は低いと推定されます。しかし、原材料の輸出入の影響は、予測期間中、世界のブレストイメージング市場の成長にほとんど影響を与えないと予測されます。

目次

第1章 調査手法と調査範囲

第2章 定義と概要

第3章 エグゼクティブサマリー

第4章 市場力学

  • 影響要因
    • 促進要因
      • 技術の進歩と新製品の上市の増加
      • 乳がん罹患率の上昇
    • 抑制要因
      • 機器別制限
    • 機会
      • 研究開発と新製品上市の増加
    • 影響分析

第5章 産業分析

  • ポーターの5フォース分析
  • サプライチェーン分析
  • 価格分析
  • 規制分析

第6章 COVID-19分析

第7章 モダリティ別

  • X線源
    • マンモグラフィ
    • デジタル乳房トモシンセシス
    • 造影デジタルマンモグラフィ
  • 超音波
    • 超音波検査
    • 造影超音波
    • 三次元超音波
    • カラードップラー/パワードップラー
    • 組織弾性イメージング
  • 磁場
    • 磁気共鳴イメージング
    • 磁気共鳴分光法
    • 拡散強調イメージング
  • ガンマ線
    • 陽電子放射断層撮影
    • 単光子放出コンピュータ断層撮影法
  • 非電離放射線
    • 光イメージング
    • 乳房マイクロ波イメージング

第8章 アプリケーション別

  • 乳がん
  • 乳腺疾患
  • その他

第9章 エンドユーザー別

  • 病院
  • 画像診断センター
  • 専門クリニック
  • その他

第10章 地域別

  • 北米
    • 米国
    • カナダ
    • メキシコ
  • 欧州
    • ドイツ
    • 英国
    • フランス
    • スペイン
    • イタリア
    • その他欧州
  • 南米
    • ブラジル
    • アルゼンチン
    • その他南米
  • アジア太平洋
    • 中国
    • インド
    • 日本
      • その他アジア太平洋地域
  • 中東およびアフリカ
    • 主な地域別ダイナミクス

第11章 競合情勢

  • 競合シナリオ
  • 市況/シェア分析
  • M&A分析

第12章 企業プロファイル

  • GE Healthcare
    • 会社概要
    • 製品ポートフォリオと説明
    • 財務概要
    • 主な発展
  • Siemens Healthcare GmbH
  • FUJIFILM Corporation
  • Koninklijke Philips NV
  • Hologic, Inc.
  • Canon Medical Systems Corporation
  • General Medical Merate S.p.A.
  • Konica Minolta Healthcare Americas, Inc.
  • Metaltronica S.p.A
  • Planmed OY

第13章 付録

目次
Product Code: MI878

Market Overview

The Global Breast Imaging Market reached US$ 4.2 billion in 2022 and is projected to witness lucrative growth by reaching up to US$ 7.9 billion by 2030. The global breast imaging market is expected to exhibit a CAGR of 8.4% during the forecast period 2023-2030. The increasing technological advancements and the growing investments in novel products are driving up demand for breast imaging market trends.

The market for breast imaging includes modalities and applications that establish the existence of the products. Despite being more common in women, breast cancer can also affect men. Ultrasound, nuclear imaging MRI, mammography, and thermography are the breast imaging procedures most frequently used to detect breast cancer and associated diseases. The launch of new modalities and an increase in patients with cancer are the main factors propelling the global market for breast imaging.

The breast imaging market scope comprises application as breast cancer, breast diseases and others, which has increased the breast imaging market share. The global market for breast imaging is expanding as a result of factors including increasing research and development and their upcoming novel product approvals across countries are also creating a positive outlook for the breast imaging market growth.

Market Dynamics

Rising Technological Advancements will Drive the Growth of the Breast Imaging market

Mammography has existed as a crucial component of the radiologist's breast cancer imaging toolset. Since its creation, it has dramatically lowered the disease's mortality rates and is a crucial screening and diagnostic tool for the prompt identification of breast cancer.

Mammography has advanced alongside technology, going from film through digital mammography to digital breast tomosynthesis (DBT). To increase cancer detection rates, decrease false positives, and improve outcomes, each evolution has kept tackling the issues that radiologists face and the worries of patients.

Contrast-enhanced mammography (CEM), which may be the next development in breast imaging, is the result of this evolution. Although the technology was created almost 10 years ago, it has only lately begun to attract attention as a result of an emerging body of research that highlights its advantages over conventional supplementary imaging.

To help detect abnormalities in breast tissue, CEM uses the same contrast material as computed tomography (CT) technology. The contrast agent flows through the breast tissue via blood vessels and accumulates wherever lesions are forming and increasing, using similar physical imaging concepts as CT and magnetic resonance imaging (MRI).

Rising Research and Development and Novel Product Launches creates Lucrative Opportunities for Manufacturers

Women between the ages of 50 and 74 who have an average risk of developing breast cancer are advised by the USPSTF to undergo a mammogram once every two years. When to begin and how frequently to obtain a mammogram should be discussed with a doctor or another physician by women between the ages of 40 and 49.

For instance, in May 2022, Therapixel, an organization for women's health that creates AI-based software, unveiled MammoScreen 2D and 3D, its most recent version of which can use prior mammograms in analysis. By comparing its performance to earlier tests, MammoScreen becomes more effective.

Limitations Associated with Equipment Will Hamper the Growth of the Market.

Not every kind of breast cancer will be discovered with a 20-year breast cancer screening schedule of every two years. 77 women out of 1,000 who undergo a mammography every two years for 20 years will develop breast cancer. 21 of them will receive cancer diagnoses while having normal mammogram results.

This can happen if: every person with breast cancer will survive; The cancer was not detected on the mammogram; The cancer had not yet been established at the point of the mammography. It is predicted that 13 women out of 1,000 who receive mammograms every two years for 20 years will pass away from breast cancer. A mammography is an X-ray as well. Radiations are released during X-ray exams like with all others.

COVID-19 Impact Analysis

The COVID-19 epidemic and the worldwide lockdown have had an effect on the financial health of businesses in all industries. As a result, the U.S. Food and Drug Administration (FDA) released guidelines for the duration of the COVID-19 health emergency that include general considerations to assist sponsors and researchers, ensure trial participants' safety, follow good clinical practice (GCP), and reduce risks to trial integrity.

Russia-Ukraine War Impact Analysis

The Russia-Ukraine conflict is estimated to have a low impact on the global breast imaging market, owing to the low number of key market players in this region. However, the impact of the import and export of raw materials is expected to have little influence over the global breast imaging market growth over the forecast period.

Segment Analysis

The global breast imaging market is segmented based on modalities, application, end-user and region.

Breast Cancer From the Application Segment Accounts for 62.8% of the Market Share Owing to the High Incidence

Cancer is a condition when the body's cells proliferate out of control. Aside from skin cancer, breast cancer is the most common type of cancer in women in the US. Breast cancer remains the second-leading cause of cancer deaths amongst all women and is particularly prevalent among Hispanic women, despite a decline in the number of fatalities from the disease over time.

In the US, around 2,400 men and 264,000 women receive a breast cancer diagnosis each year. Each year, breast cancer claims the lives of 42,000 women and 500 men in the United States. Black women suffer from a higher breast cancer death rate than White women. Breast ultrasonography and mammography along with MRI can be helpful diagnostic tools.

According to recent studies, MRI can find some tiny breast tumors that mammography occasionally misses. Additionally, it can aid in the early detection of breast cancer in younger women with dense breast tissue and in those who have breast implants. Mammography might not be as useful in these circumstances. MRIs don't use radiation, so they can be used to screen people under 40 and increase the number of tests for people who are at elevated risk for breast cancer each year.

Geographical Analysis

North America Accounted for Approximately 39.6% of the Market Share Owing to the Strong Presence of Major Players and the Advancements in Breast Imaging

Manufacturers have chances to expand their operations in this region because of the rising demand for Breast Imaging for advancements in North America. The area has many producers and suppliers, and its rapid economic development has raised industrial production of Breast Imaging, which has increased the demand.

There are many manufacturers and suppliers in North America, and as a result of the region's rapid economic growth, industrial production has expanded, feeding the desire for research and development of novel products.

The market will grow as new technology for research and development emerge. Rising technological developments, governmental approvals, and the introduction of new products all contribute to growth. People are becoming more aware of novel products and therapies, leading to the expansion of the market in this region. These factors are responsible for the dominance of North America.

Competitive Landscape

The major global players in the breast imaging market include: GE Healthcare, Siemens Healthcare GmbH, FUJIFILM Corporation, Koninklijke Philips NV, Hologic, Inc., Canon Medical Systems Corporation, Inc., General Medical Merate S.p.A., Konica Minolta Healthcare Americas, Inc., Metaltronica S.p.A and Planmed OY among others.

Why Purchase the Report?

  • To visualize the global breast imaging market segmentation based on modalities, applications, end-user and region, as well as understand key commercial assets and players.
  • Identify commercial opportunities by analyzing trends and co-development.
  • Excel data sheet with numerous data points of breast imaging market-level with all segments.
  • PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
  • Product mapping available as Excel consisting of key products of all the major players.

The global breast imaging market report would provide approximately 53 tables, 54 figures and 195 Pages.

Target Audience 2023

  • Manufacturers / Buyers
  • Industry Investors/Investment Bankers
  • Research Professionals
  • Emerging Companies

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

  • 3.1. Snippet by Modalities
  • 3.2. Snippet by Application
  • 3.3. Snippet by End-User
  • 3.4. Snippet by Region

4. Dynamics

  • 4.1. Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Increasing Technological Advancements and Novel Product Launches
      • 4.1.1.2. The Rising Incidence of Breast Cancer
    • 4.1.2. Restraints
      • 4.1.2.1. Limitations Associated with Equipment
    • 4.1.3. Opportunity
      • 4.1.3.1. Rising Research and Development and Novel Product Launches
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's 5 Force Analysis
  • 5.2. Supply Chain Analysis
  • 5.3. Pricing Analysis
  • 5.4. Regulatory Analysis

6. COVID-19 Analysis

  • 6.1. Analysis of COVID-19
    • 6.1.1. Scenario Before COVID-19
    • 6.1.2. Scenario During COVID-19
    • 6.1.3. Scenario Post COVID-19
  • 6.2. Pricing Dynamics Amid COVID-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During the Pandemic
  • 6.5. Manufacturers' Strategic Initiatives
  • 6.6. Conclusion

7. By Modalities

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Modalities
    • 7.1.2. Market Attractiveness Index, By Modalities
  • 7.2. X-Ray Source *
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
    • 7.2.3. Mammography
    • 7.2.4. Digital Breast Tomosynthesis
    • 7.2.5. Contrast-Enhanced Digital Mammography
  • 7.3. Ultrasound
    • 7.3.1. Sonography
    • 7.3.2. Contrast-Enhanced Ultrasound
    • 7.3.3. Three-Dimensional Ultrasound
    • 7.3.4. Color/Power Doppler
    • 7.3.5. Tissue Elasticity Imaging
  • 7.4. Magnetic Field
    • 7.4.1. Magnetic Resonance Imaging
    • 7.4.2. Magnetic Resonance Spectroscopy
    • 7.4.3. Diffusion-Weighted Imaging
  • 7.5. Gamma Radiation
    • 7.5.1. Positron Emission Tomography
    • 7.5.2. Single-Photon Emission Computed Tomography
  • 7.6. Non-Ionizing Radiation
    • 7.6.1. Optical Imaging
    • 7.6.2. Breast Microwave Imaging

8. By Application

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 8.1.2. Market Attractiveness Index, By Application
  • 8.2. Breast Cancer *
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 8.3. Breast Disease
  • 8.4. Others

9. By End-User

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 9.1.2. Market Attractiveness Index, By End-User
  • 9.2. Hospitals *
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 9.3. Diagnostic Imaging Centres
  • 9.4. Specialty Clinics
  • 9.5. Others

10. By Region

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
    • 10.1.2. Market Attractiveness Index, By Region
  • 10.2. North America
    • 10.2.1. Introduction
    • 10.2.2. Key Region-Specific Dynamics
    • 10.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Modalities
    • 10.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 10.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 10.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.2.6.1. The U.S.
      • 10.2.6.2. Canada
      • 10.2.6.3. Mexico
  • 10.3. Europe
    • 10.3.1. Introduction
    • 10.3.2. Key Region-Specific Dynamics
    • 10.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Modalities
    • 10.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 10.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 10.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.3.6.1. Germany
      • 10.3.6.2. The U.K.
      • 10.3.6.3. France
      • 10.3.6.4. Spain
      • 10.3.6.5. Italy
      • 10.3.6.6. Rest of Europe
  • 10.4. South America
    • 10.4.1. Introduction
    • 10.4.2. Key Region-Specific Dynamics
    • 10.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Modalities
    • 10.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 10.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 10.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.4.6.1. Brazil
      • 10.4.6.2. Argentina
      • 10.4.6.3. Rest of South America
  • 10.5. Asia-Pacific
    • 10.5.1. Introduction
    • 10.5.2. Key Region-Specific Dynamics
    • 10.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Modalities
    • 10.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 10.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 10.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.5.6.1. China
      • 10.5.6.2. India
      • 10.5.6.3. Japan

Australia

      • 10.5.6.4. Rest of Asia-Pacific
  • 10.6. Middle East and Africa
    • 10.6.1. Introduction
    • 10.6.2. Key Region-Specific Dynamics
    • 10.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Modalities
    • 10.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 10.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User

11. Competitive Landscape

  • 11.1. Competitive Scenario
  • 11.2. Market Positioning/Share Analysis
  • 11.3. Mergers and Acquisitions Analysis

12. Company Profiles

  • 12.1. GE Healthcare *
    • 12.1.1. Company Overview
    • 12.1.2. Product Portfolio and Description
    • 12.1.3. Financial Overview
    • 12.1.4. Key Developments
  • 12.2. Siemens Healthcare GmbH
  • 12.3. FUJIFILM Corporation
  • 12.4. Koninklijke Philips NV
  • 12.5. Hologic, Inc.
  • 12.6. Canon Medical Systems Corporation
  • 12.7. General Medical Merate S.p.A.
  • 12.8. Konica Minolta Healthcare Americas, Inc.
  • 12.9. Metaltronica S.p.A
  • 12.10. Planmed OY

LIST NOT EXHAUSTIVE

13. Appendix

  • 13.1. About Us and Services
  • 13.2. Contact Us